Vertex Pharmaceuticals Inc. notched two FDA victories ... Vertex also won expanded approval for Trikafta, which was first approved in 2019. Trikafta has become Vertex’s (Nasdaq: VRTX ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...

As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has chalked up a win in its specialty area of cystic fibrosis. The FDA has ...

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...

According to Vertex Pharmaceuticals, approximately 300 additional ... 6 years and older with at least 1 qualifying non-F508del Trikafta-responsive mutation and with no exclusionary mutation.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.

Vertex Pharmaceuticals’ shares have lost 2.3% compared with the industry’s 13.7% decline. In a separate press release, Vertex announced that the FDA has expanded Trikafta’s label to include ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor ...

Vertex Pharmaceuticals stock was heading for a ... But Vertex's newest blockbuster, Trikafta -- approved in 2019 -- made a splash when it entered the market because it can be used for about ...

Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.